FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm
Erin JungmeyerDuring the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC. Read more
Antibody Drug Conjugates: Diamonds in the Rough?
Matthew Lee, MD, MPH+more
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact. Read more
The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology
Jan von der Thüsen, MD, PhD+more
Profs. Jan von der Thüsen and John Le Quesne say while still in the early phases, AI has the potential to bring accessible and affordable prognosis and response prediction tools to all. Read more
The filing was based on results from a global phase III study designed to compare the ALK inhibitor to crizotinib in the first-line treatment of ALK-positive NSCLC. Read more
IASLC Launches Global Member Survey on Diversity, Equity, and Inclusion
Erin JungmeyerThe association seeks input from members to better understand the current DEI landscape so it can continue to build a diverse international community dedicated to the elimination of thoracic malignancies. Read more
Regulating Artificial Intelligence
Erin JungmeyerThe US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective. Read more
Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC
Erin JungmeyerIn light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting. Read more
Should Biomarkers Be Used in the Clinical Management of ES-SCLC?
Erin JungmeyerDuring a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space. Read more
The move was supported by preliminary evidence from a phase I, first-in-human study in patients with advanced NSCLC. Read more
Lung Cancer 360 offers a centralized hub for thoracic oncology learning opportunities spanning multiple disciplines and formats. Read more